Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to freeze ovarian tissue for transgender fertility

NCT ID NCT05863676

Knowledge-focused Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at how to best freeze and store ovarian tissue for transgender individuals who are undergoing gender-affirming therapy. The goal is to preserve the possibility of having biological children later. Researchers will test different freezing methods and examine how hormone treatments affect the tissue. Participants are transgender individuals with ovaries who are planning or already receiving gender-affirming hormones.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could improve fertility preservation options for transgender individuals who cannot or do not wish to undergo natal puberty.
What could go wrong
This is a small, early-stage study focused on tissue analysis, not on actual fertility outcomes. The techniques may not lead to successful pregnancies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients who will undergo gender-affirming treatments and for whom standard of care fertility preservation procedures are not available.

Ages

9 years and older

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Two Categories of participants will be eligible for this study. Category 1 participants must have all criteria listed below: * Patient with ovaries over the age of 9 * Diagnosed with gender dysphoria; currently on or imminently planning to start gender affirming treatment (hormone blockers or gender-affirming hormones) * Have a clinical referral for fertility preservation from their primary care physician * Unwilling to undergo natal puberty or, for patients who have gone through puberty, unwilling to discontinue hormone suppression and/or hormone replacement therapy. Category 2 participants only fall into this category if they are undergoing gender-affirming surgery. They must have all criteria listed below: * Patient is 18+ years old * Diagnosed with gender dysphoria * Unwilling to undergo natal puberty, or for patients who have gone through puberty, be unwilling to discontinue hormone suppression and/or sex steroid (estrogen) therapy. * Will be undergoing gender affirming surgery that involves removal of the ovaries. Exclusion Criteria: * Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent. * Diagnosed with an underlying medical condition that significantly increases their risk of complications from anesthesia and surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gender dysphoria are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Gender Dysphoria infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gender dysphoria Transgender

Contacts and locations

Locations

  • Magee-Womens Hospital

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.